{
  "catalysts": [
    {
      "ticker": "OMER",
      "conviction_score": 10,
      "thesis": "FDA approval of Yartemlea (narsoplimab) for TA-TMA marks a transformative commercial milestone, validated by an 81% stock surge.",
      "catalyst_details": "FDA approved Yartemlea on Dec 29, 2025 (reported), the first treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy. Launch set for Jan 2026.",
      "sentiment": "Bullish",
      "prediction_market": "Stock surged 81% post-approval; Market effectively priced near-0% chance of rejection given the move.",
      "recency_proof": "Zacks Investment Research (Dec 29, 2025) - 'Omeros Gets FDA Approval for YARTEMLEA...'",
      "risk": "Commercial execution and reimbursement uptake hurdles in early 2026."
    },
    {
      "ticker": "IMMR",
      "conviction_score": 9,
      "thesis": "Significant earnings miss on Dec 31 signals deteriorating core business fundamentals despite haptic tech potential.",
      "catalyst_details": "Q4 Earnings released Dec 31, 2025. EPS reported $0.08 vs $0.14 estimate (-41.43% surprise).",
      "sentiment": "Bearish",
      "prediction_market": "Analyst Consensus: Strong Buy (Target $12.50) failed to predict the -41% EPS miss.",
      "recency_proof": "TradingView Earnings Calendar (Dec 31, 2025) - 'Reported EPS 0.08... Surprise -41.43%'",
      "risk": "Potential patent litigation wins or unexpected licensing deals could reverse sentiment."
    },
    {
      "ticker": "NVO",
      "conviction_score": 9,
      "thesis": "FDA approval of oral Wegovy cements dominance in obesity market, providing a critical moat against Eli Lilly's entry.",
      "catalyst_details": "FDA approved oral Wegovy (semaglutide 25mg) for weight loss. News circulated/updated Dec 30, 2025.",
      "sentiment": "Bullish",
      "prediction_market": "Polymarket 'Obesity Drug Dominance' (Proxy); Stock rallied ~2.5% on news, confirming market approval pricing.",
      "recency_proof": "Healthcare Finance News (Dec 30, 2025) - 'FDA approves Wegovy pill...'",
      "risk": "Competition from Eli Lilly's orforglipron (oral GLP-1) expected in 2026."
    },
    {
      "ticker": "CVM",
      "conviction_score": 8,
      "thesis": "Earnings surprise and reduced burn rate indicate operational efficiency ahead of pivotal Multikine registration trial.",
      "catalyst_details": "Earnings reported Dec 29, 2025. Stock rose 4.8%, defying options market implied volatility of ±19.9%.",
      "sentiment": "Mixed",
      "prediction_market": "Options Market: Implied Move ±19.9% vs Actual +4.8% (Volatility Crush).",
      "recency_proof": "MarketChameleon (Dec 29, 2025) - 'CVM Earnings Surprise: Stock Climbs 4.8%'",
      "risk": "Historical tendency for stock to fade post-earnings; Multikine trial risks remain binary."
    }
  ]
}